Aberdeen Group’s NewAmsterdam Pharma NAMS Stock Holding History

Aberdeen Group’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.4M	Buy	1,102,785 +265,780	+32%	+$8.76M	0.05%	280
2026 Q1	$26.8M	Buy	837,005 +107,521	+15%	+$3.5M	0.04%	334
2025 Q4	$25.6M	Buy	729,484 +67,538	+10%	+$2.46M	0.04%	346
2025 Q3	$18.8M	Sell	661,946 -73,086	-10%	-$1.75M	0.03%	457
2025 Q2	$13.3M	Buy	735,032 +358,169	+95%	+$6.53M	0.02%	532
2025 Q1	$7.71M	Buy	376,863 +197,803	+110%	+$4.4M	0.02%	624
2024 Q4	$4.6M	Buy	179,060 +50,000	+39%	+$1.06M	0.01%	662
2024 Q3	$2.14M	Buy	129,060 +53,060	+70%	+$918K	﹤0.01%	751
2024 Q2	$1.46M	Buy	+76,000	New	+$1.52M	﹤0.01%	787

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Aberdeen Group's NAMS Position: Q2 2026 in Review

Aberdeen Group increased its NewAmsterdam Pharma (NAMS) stake by 32% in Q2 2026, buying an estimated $8.76M and bringing the position to 1,102,785 shares worth $37.4M. The position accounts for 0.05% of the portfolio, ranked #280.

Aberdeen Group first reported a position in NAMS in Q2 2024 and has held it in 9 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Aberdeen Group held 1,102,785 shares of NewAmsterdam Pharma worth $37.4M as of Q2 2026.
Aberdeen Group bought 265,780 NewAmsterdam Pharma shares in Q2 2026, an estimated $8.76M.
NewAmsterdam Pharma made up 0.05% of Aberdeen Group's portfolio in Q2 2026, its #280 holding.
Aberdeen Group first reported a position in NewAmsterdam Pharma in Q2 2024 and has held it in 9 quarters since.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.